Narrator: This is Science Today. There's been lots of press about future cancer therapies utilizing both the body's own immune system and carefully targeted toxic drugs to fight against tumors. Oncologist John Park of the University of California, San Francisco says although such approaches have been recognized for years, it takes time to get to the public. Such is the case, he says, with liposomes, synthetic particles used to deliver anti-cancer drugs to tumor cells.
Park: Liposomes have been around for a couple of decades and only in the last few years have they finally, just liposomes alone, finally reached clinical use and been approved for the treatment of Kaposi's Sarcoma, which is an uncommon cancer but an important cancer in HIV patients.
Narrator: Park and his colleagues are working on immunoliposomes, which are equipped with antibodies that seek out and destroy tumor cells.
Park: Although people have been interested in immunoliposomes and targeted delivery like this also for a long time, it's just taken a while to build a better mousetrap, so to speak, or to make something that really does do what it's supposed to do.
Narrator: For Science Today, I'm Larissa Branin.